INTRODUCTION AND OBJECTIVES: Intermediate-risk category of non-muscle invasive bladder cancer comprises a very heterogeneous population.
INTRODUCTION AND OBJECTIVES: About 75% of urothelial carcinoma of the bladder are non-invasive (non muscle-invasive bladder cancer, NMIBC), therefore limited to mucosa (Ta or CIS) or sub-mucous (T1). Several studies have shown that androgens are implicated in bladder carcinogenesis: the increase in androgen expression and androgen receptors have a positive effect on oncogenic expression, which can lead to an increase of those specific proteins that promote the proliferation, invasiveness and motility of neoplastic cells. The aim of the study was to evaluate whether 5-alpha reductase inhibitors (5-ARI) have a role in NMIBC.
METHODS: The retrospective analysis was conducted on 252 patients diagnosed with NMIBC who underwent trans urethral resection of the bladder (TURB), from 2013 to 2018. The study was conducted evaluating demographic characteristic of each patient, intraoperative and postoperative parameters. We analyzed the number of resections, number of total recurrences, time of recurrences, and histopathology details. The population was divided in two main groups: treated and untreated whit 5-ARIs. Patients were treated with dutasteride for lower urinary tract symptoms due to prostatic hyperplasia (mean treatment time 16.8 months) The patients were followed according to EAU follow-up guidelines for NIMBC. Mean follow-up time was 29.5 months (range 24-50 months).
RESULTS: No significant differences were observed among the different groups at baseline. The group treated with 5-ARIs presented a lower rate of recurrences (14.78%) than the untreated group (37.11%). Regarding the mean number of recurrences statistically significant difference was observed between the untreated (1.944 AE SD 0.141) and the treated group (1.235; AE SD 0.206; p value: 0.0066), respectively. Furthermore, evaluating the recurrences, the 5-ARIs group showed a lower T stage when compared to untreated group (p value [ 0.037). No significant differences were obtained regarding the grade of the recurrences (p value [ 0.756).
CONCLUSIONS: Long-term treatment with 5-alpha reductase inhibitors might play a role on reducing the risk of tumor recurrence and pT and extension of the lesions. Starting from this experience, a long-term, randomized prospective study could definitively assess the possible role of this widely used drugs in NMIBC.
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